Urologia internationalis · 2026
Efficacy and Safety of Muscarinic Antagonists Combined with Adrenergic Alpha-Antagonists in the Medical Expulsion Therapy for Distal Ureteral Stone: A Meta-Analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Chuanjian, Mo Chunhao, Zhang Shaolong, Ning Zhongyun, Hou Zizhen, Fan Ning, Ding Hui
Аннотация
INTRODUCTION: Lower ureteral stones, due to their proximity to the bladder, frequently cause irritation symptoms and voiding disturbances. The efficacy of combining adrenergic alpha-antagonists with muscarinic antagonists in improving stone expulsion and alleviating lower urinary tract symptoms remains uncertain. This meta-analysis aimed to evaluate the clinical benefit of such combination therapy for distal ureteral calculi.
METHODS: A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, Web of Science, and major Chinese databases through October 2024. Only randomised controlled trials comparing combination therapy with monotherapy were included. The quality of evidence was assessed using the GRADE framework, and meta-analyses were performed using RevMan 5.3 software.
RESULTS: Eight RCTs comprising 800 patients were included. Combination therapy significantly improved stone expulsion rates compared to either alpha-blockers alone (risk ratio [RR] = 1.13; p = 0.04) or muscarinic antagonists alone (RR = 1.53; p < 0.00001). It also reduced pain episodes (mean difference = -0.75; p < 0.0001) and severity (VAS) and improved urgency symptoms (USS) at 3 and 7 days. No significant difference in stone expulsion time was observed. Constipation and dry mouth were more common in the combination group.
CONCLUSION: Combination therapy with alpha-blockers and muscarinic antagonists improves stone expulsion and symptomatic relief in patients with lower ureteral stones <10 mm, without significantly affecting stone passage time, but at the cost of more anticholinergic side effects.
METHODS: A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, Web of Science, and major Chinese databases through October 2024. Only randomised controlled trials comparing combination therapy with monotherapy were included. The quality of evidence was assessed using the GRADE framework, and meta-analyses were performed using RevMan 5.3 software.
RESULTS: Eight RCTs comprising 800 patients were included. Combination therapy significantly improved stone expulsion rates compared to either alpha-blockers alone (risk ratio [RR] = 1.13; p = 0.04) or muscarinic antagonists alone (RR = 1.53; p < 0.00001). It also reduced pain episodes (mean difference = -0.75; p < 0.0001) and severity (VAS) and improved urgency symptoms (USS) at 3 and 7 days. No significant difference in stone expulsion time was observed. Constipation and dry mouth were more common in the combination group.
CONCLUSION: Combination therapy with alpha-blockers and muscarinic antagonists improves stone expulsion and symptomatic relief in patients with lower ureteral stones <10 mm, without significantly affecting stone passage time, but at the cost of more anticholinergic side effects.